<p>Aclaris Therapeutics Inc :</p>
<ul>
<li>Aclaris Therapeutics 宣佈 ATI-2138 的開放標籤 2A 期臨牀試驗取得積極的頂線結果，ATI-2138 是一種強效且選擇性的 ITK 和 JAK3 研究性抑制劑；試驗達成主要和關鍵次要終點</li>
<li>Aclaris Therapeutics Inc - 主要終點確認 ATI-2138 具有良好的耐受性特徵</li>
<li>Aclaris Therapeutics Inc - ATI-2138 耐受良好，沒有嚴重不良事件</li>
</ul>

ACRS

<p>Aclaris Therapeutics Inc：Aclaris Therapeutics 宣佈 ATI-2138 的開放標籤 2A 期試驗取得積極的頂線結果，ATI-2138 是一種強效且選擇性的 ITK 和 JAK3 抑制劑；試驗達成主要和關鍵次要終點。Aclaris Therapeutics Inc - 主要終點確認 ATI-2138 具有良好的耐受性。Aclaris Therapeutics Inc - ATI-2138 耐受良好，沒有嚴重不良事件</p>

<p>Aclaris Therapeutics Inc :</p>
<div class="lb-trans"><p>Aclaris Therapeutics Inc :</p>
</div><ul>
<li>ACLARIS THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM OPEN-LABEL PHASE 2A TRIAL OF ATI-2138, A POTENT AND SELECTIVE INVESTIGATIONAL INHIBITOR OF ITK AND JAK3; TRIAL ACHIEVES PRIMARY AND KEY SECONDARY ENDPOINTS</li>
<li>ACLARIS THERAPEUTICS INC - PRIMARY ENDPOINT CONFIRMS FAVORABLE TOLERABILITY PROFILE OF ATI-2138</li>
<li>ACLARIS THERAPEUTICS INC - ATI-2138 WELL TOLERATED WITH NO SEVERE ADVERSE EVENTS</li>
</ul>
<div class="lb-trans"><ul>
<li>Aclaris Therapeutics 宣佈 ATI-2138 的開放標籤 2A 期臨牀試驗取得積極的頂線結果，ATI-2138 是一種強效且選擇性的 ITK 和 JAK3 研究性抑制劑；試驗達成主要和關鍵次要終點</li>
<li>Aclaris Therapeutics Inc - 主要終點確認 ATI-2138 具有良好的耐受性特徵</li>
<li>Aclaris Therapeutics Inc - ATI-2138 耐受良好，沒有嚴重不良事件</li>
</ul>
</div>

Aclaris Therapeutics Announces Positive Top-Line Results From Open-Label Phase 2A Trial Of Ati-2138, A Potent And Selective Investigational Inhibitor Of Itk And Jak3 Trial Achieves Primary And Key Secondary Endpoints